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Objectives: This study aims to increase understanding of the connection between oxidative stress and in-
ﬂammation in diabetes disease progression to provide a basis for investigating improved diagnostic possibilities,
treatment and prevention of prediabetes.
Design and methods: Differences in the level of biochemical markers of oxidative stress (erythrocyte GSH/
GSSG and urinary 8-isoprostane), inﬂammation (CRP, IL-6), endothelial dysfunction (plasma homocysteine, uri-
nary 8-hydroxy-2-deoxy-guanosine) and coagulation/ﬁbrinolysis (C5a, D-Dimer) were determined in prediabe-
tes and control subjects.
Results:While no difference was found in the 8-isoprostane levels between the two groups, the erythrocyte
GSH/GSSG ratiowas signiﬁcantly reduced in the prediabetes group compared to control, indicating increased ox-
idative stress in the prediabetic state. Both urinary 8-OHdG and surprisingly also plasma homocysteine were sig-
niﬁcantly elevated in the prediabetes group, indicating endothelial dysfunction. The inﬂammationmarkers were
slightly elevated in the prediabetic subjects and the same trend was found for the coagulation/ﬁbrinolysis
markers C5a and D-Dimer. These results were however not signiﬁcant.
Conclusions: The small elevation of blood glucose levels in the prediabetic state may have a detectable inﬂu-
ence on endothelial function as indicated by changes to 8-OHdG, indicating an increased DNA-damage and ho-
mocysteine release from endothelial cells. Increased oxidative stress as indicated by the reduced GSH/GSSG
ratio is likely to be the link between themoderate hyperglycaemia in prediabetes and pathological changes in en-
dothelial function, which in the long-termmay promote atherogenesis and result in the development of cardio-
vascular disease. Early detection of prediabetes is essential to avoid diabetes development and the associated
complications like cardiovascular disease. The GSH/GSSG ratio and biomarkers like urinary 8-OHdG and plasma
homocysteine offer a possible tool for the assessment of prediabetes in prevention screenings.
© 2015 The Authors. The Canadian Society of Clinical Chemists. Published by Elsevier Inc. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Diabetes mellitus is a global health problem affectingmore than 6% of
the world population and its prevalence is estimated to increase to about
552million in 2030 [1]. These numbers do not include the amount of peo-
ple with prediabetes, of which 90% is unaware of their situation [2]. The
resulting socio-economic burden calls for additional diagnostic and ther-
apeutic strategies to prevent the onset of diabetes efﬁciently.vanced Medicine, Macquarie
ty of Clinical Chemists. PublishedDiabetesmellitus, which is deﬁned as a fasting blood glucose level of
greater than 6.9 mmol/L [3] is associated with extensive organ dysfunc-
tion including diabetic retinopathy, kidney disease and cardiovascular
disease (CVD), gastrointestinal disturbance, sexual dysfunction and di-
abetic neuropathy [4,5]. The fatal macrovascular complications account
for the majority of deaths among patients with diabetes mellitus [6].
A fact to take into considerationwhen it comes to primary prevention
of CVD is that cardiovascular risk is already increased in people with im-
paired glucose tolerance [7], i.e. in the prediabetic state, which is deﬁned
by an impaired fasting blood glucose level of 5.6–6.9 mmol/L [3]. Studies
show that impaired fasting glucose is not just a precursor of diabetes, but
an individual risk factor formortality [8]. The prevalence of prediabetes isby Elsevier Inc. This is an open access article under the CC BY-NC-ND license
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and, if untreated, will progress to diabetes and the associated complica-
tions [7]. The key to prevention of diabetes development and its vascular
complications are therefore early detection and treatment of prediabetes.
A major part of understanding disease progression is to unravel
pathological processes associated with asymptomatic or preclinical
stages of disease. For screening of preclinical presentations of disease a
number of criteria as recommended by the World Health Organization
(WHO) have to bemet. These include: (1) The condition being screened
for should be an important health problem, (2) There should be a de-
tectable early stage, (3) Treatment at an early stage should be of more
beneﬁt than at a later stage, and (4) A suitable test should be devised
for the early stage [9]. It has been shown that the onset of type 2 diabe-
tes can be prevented or delayed by a combination of change in diet,
moderate exercise and modest weight loss [2]. Early detection and in-
tervention may already have an effect on reducing prediabetes and its
adverse effect on optimal physiological function.
Biomarkers have played an important role in identifying and charac-
terizing pathological processes with blood glucose levels (BGL), HbA1c
and cholesterol levels having been measured as part of clinical assess-
ment of diabetes and cardiovascular disease for many years [10]. The
role of biomarkers is increasing as technical advancements allow more
accurate investigation of biochemical processes involved in disease pro-
gression. Inﬂammatory markers such as C-reactive protein (CRP) and
interleukins (IL′s) have been shown to predict development of type 2
diabetes [11] and are now used routinely in medical practice to screen
for cardiovascular disease [12,13].
Diabetes progression is, however, not only connected with changes
in traditional biomarkers such as BGL, HbA1c and cholesterol, but also
inﬂammatory, endothelial dysfunction, oxidative stress and autonomic
nervous system markers have been reported to be elevated in diabetes
[12,14–20]. These include tumor necrosis factorα (TNFα), antioxidants
such as reduced glutathione (GSH) and vitamin E (α-tocopherol), lipid
peroxidation products such as malondialdehyde (MDA) and
isoprostanes as well as markers of endothelial dysfunction including
8-hydroxy-2-deoxy-guanosine (8-OHdG) and homocysteine (Hcy)
[12,14–20].
Current therapeutic interventions aim to reach certain target levels
deemed to be appropriate to maintain health or reduce risk of disease
progression. Statin use has been shown to be effective as it reduces
LDL and triglycerides and increases HDL [21,22]. In addition, there is ev-
idence that statins have antioxidant activity [23], but they do not neces-
sarily lead to an improved CVD risk [24].
The association between oxidative stress and cardiovascular disease
in diabetes via endothelial dysfunction and the resulting pathological
changes in inﬂammation, coagulation status and cell-proliferation has
been extensively investigated [18,25–27]. In the case of prediabetes,
the situation is less understood [28,29], but changes in redox-status
and the onset of hyperglycaemia-associated complications are already
identiﬁable before diabetes diagnosis [20]. The central mechanism that
is responsible for the increased cardiovascular risk in prediabetes is en-
dothelial dysfunction due to the elevated formation of reactive oxygen
species (ROS) and advanced glycation end products (AGEs) as well as in-
creased lipid peroxidation under hyperglycaemic conditions [30–34]. The
consequences of endothelial dysfunction include impaired balance be-
tween coagulation and ﬁbrinolysis, platelet activation, vascular smooth
muscle cell proliferation and stimulation of inﬂammatory processes,
which all together create a pro-thrombotic environment and, if
hyperglycaemia remains untreated, cause cardiovascular disease in the
long-term [32,33].
The association between biomarkers and disease progression from
normal to impaired fasting blood glucose (prediabetes) has not been
studied extensively. Al-Aubaidy and Jelinek have recently shown that
8-OHdG is elevated already in the prediabetic state, suggesting an im-
pact on pathological processes of even moderate increases in BGL [29].
If reliable and speciﬁc biomarkers for the prediabetic state can beestablished, early detection and treatment of prediabetes could slow
down the worldwide diabetes epidemic.
This study aims to increase the understanding of the connection
between oxidative stress and inﬂammation in prediabetes disease
progression. The results of this study aim toprovide a basis for improved
diagnostic possibilities for detecting changes in prediabetes earlier, im-
proved treatment and prevention in regular population screenings of
people at increased risk of developing diabetes and cardiovascular dis-
ease. To achieve this, differences in the level of biochemical markers of
oxidative stress (erythrocyte GSH/GSSG and urinary 8-isoprostane), in-
ﬂammation (CRP, IL-6), endothelial dysfunction (homocysteine, urinary
8-hydroxy-2-deoxy-guanosine) and coagulation/ﬁbrinolysis (C5a, D-
Dimer) were determined in prediabetes and control subjects. To our
knowledge, there has been no study so far that has investigated these
markers together in prediabetes.
Material and methods
The study was approved by the Ethics in the Human Research Com-
mittee of Charles Sturt University.
Recruitment of participants
A total of 428participants (female:male, 247:181)were selectedwith-
in a rural diabetes screening clinic at CSU for analysis of blood and urine
samples. There were no exclusion criteria for participation in this study
except for age (participants older than 40 years were included). As part
of the screening process BMI, gender, lipid proﬁle including triglycerides
(TG), HDL-cholesterol, LDL-cholesterol, TC/HDL ratio, and the atherogenic
index of plasma (AIP) were determined for all participants.
The participants were divided into two groups: a control group (FBG
b 5.6mmol/L (100mg/dL)) and a prediabetes group (FBG5.6–6.9mmol/
L (100–125 mg/dL)). Fasting blood glucose levels (FBG) for the two
groups were deﬁned according to the deﬁnition criteria of the
American Diabetes Association 2004 [3].
Chemicals
The reagents used in this studywere purchased fromCaymanChem-
ical Company (Ann Arbor, MI, USA) (Interleukin-6 (human) EIA Kit Lot
No. 0433189, Glutathione EIA Kit Lot No. 0440001 and 8-hydroxy-2-
deoxy Guanosine EIA Kit Lot No. 0439545), BD Biosciences (San Jose,
CA, USA) (Human C5a ELISA Kit II Lot No. 2146942) and Northwest
Life Science Specialties (Vancouver, WA Canada) (Urinary Isoprostane
ELISA Kit Lot No. 15002-1861).
Apparatus
Fasting blood glucose levels were determined using the Accu-Chek®
system (Roche Australia Pty Ltd) and plasma homocysteine levels were
measured with the automated AxSYM® system (Abbott Laboratories,
USA). All centrifugation procedures for the blood preparation were per-
formed with a UNIVERSAL 32R (Hettich Zentrifugen, Germany). The
photometric measurements to determine the levels of biomarkers in
blood and urine were carried out with a Thermo Scientiﬁc Multiskan
FC (Fisher, China).
Sample preparation
Venous blood was collected into EDTA-tubes to avoid coagulation,
serum-separating-tubes (SST) and sodium-citrate-(SC)-tubes tomeasure
coagulation. The EDTA-treated samples were immediately separated into
plasma and red cells by centrifugation for 15 min at 800 g and 4 °C. The
plasma was used to determine C5a, IL-6 and homocysteine levels. For
measurement of erythrocyte reduced and oxidized glutathione (GSH
and GSSG, respectively) an erythrocyte lysate was prepared by adding
Table 1
Characteristics and biomarker results of control and prediabetic subjects.
Control subjects
{n = 252}
Prediabetic subjects
{n = 176}
Age (years) 61.81 ± 11.58 66.99 ± 10.82
Sex (female/male) 151/101 96/80
Smoking (%) 1.59 0.57
Alcohol (%) 3.97 10.80
Family history DM (%) 31.35 43.18
Medication
Statins 3 (1.2%) 6 (3.41%)
Antihypertensives 13 (5.16%) 63 (35.8%)
Aspirin/clopidogrel 16 (6.35%) 27 (15.34%)
BMI 26.29 ± 4.64 28.22 ± 5.12
eGFR (mL/min/1.73 m2) 89.03 ± 16.27 88.30 ± 21.32⁎⁎
Atherogenic index −0.096 ± 0.34 −0.08 ± 0.30
HbA1c (%) 5.64 ± 0.95 5.78 ± 0.31
Total cholesterol (mmol/L) 5.49 ± 0.95 5.17 ± 1.10⁎⁎
Triglycerides (mmol/L) 2.07 ± 11.15 1.41 ± 0.99
HDL (mmol/L) 1.46 ± 0.39 1.50 ± 0.75
LDL (mmol/L) 3.45 ± 0.82 3.10 ± 0.99⁎⁎
TC/HDL ratio 3.97 ± 1.16 3.76 ± 1.01
GSH (mmol/L) 2.16 ± 0.6 2.23 ± 0.6
GSSG (mmol/L) 0.34 ± 0.2 0.39 ± 0.2
GSH/GSSG ratio 7.04 ± 5.93 5.09 ± 3.33⁎⁎
8-isoprostane (mg/mmol creatinine) 0.21 ± 0.16 0.23 ± 0.19
8-OHdG (mg/mmol creatinine) 26.45 ± 11.55 34.08 ± 15.30⁎⁎
Homocysteine (μM) 9.62 ± 2.54 10.03 ± 3.56⁎⁎
CRP (mg/L) 3.05 ± 2.30 3.69 ± 2.72⁎
IL-6 (pg/mL) 28.66 ± 28.43 34.37 ± 33.72⁎
C5a (ng/mL) 19.32 ± 20.04 21.91 ± 21.03
D-Dimer (μg/L) 0.46 ± 0.30 0.54 ± 0.37
⁎ p b 0.1.
⁎⁎ p b 0.05.
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centrifuging again for 10 min at 3000 g and 4 °C for deproteination.
Urine was collected midﬂow for determination of 8-isoprostane and 8-
OHdG.
Urine, plasma and erythrocyte lysate aliquots were either analyzed
directly or stored at −80 °C until analysis. Additional urine aliquots,
EDTA-, SST- and SC-tubes were sent to Dorevitch Pathology Laboratory,
Albury, NSW, who provided urinary creatinine values, triglycerides, the
cholesterol proﬁle, HbA1c, CRP and D-Dimer levels.
Measurement of oxidative stress
Erythrocyte GSH and GSSG were determined by the Glutathione EIA
Kit (Cayman Chemical, USA), which utilizes the enzyme glutathione re-
ductase to measure total GSH. The 5,5′-dithio-bis-2-nitrobenzoic acid
(DTNB) reaction produces the yellow colored 5-thio-2-nitrobenzoic
acid (TNB), which can be measured spectrophotometrically at 405–
414 nm and is directly proportional to total GSH concentration in the
sample. For exclusivemeasurement of GSSG, the samples and standards
were incubated with 1% of 1M 2-vinylpyridine for 60min at room tem-
perature to derivatize free GSH before performing the assay. The con-
centrations of GSH and GGSG were determined using the End Point
Method and corrected for the deproteination step [35,36].
8-isoprostane was determined by a urinary Isoprostane ELISA Kit
(Northwest, USA), which uses a competitive ELISA strategy, allowing
the 8-isoprostane contained in samples and standards to compete
with a 8-isoprostane-horseradish peroxidase conjugate for binding to
a speciﬁc antibody pre-coated on a microplate. The blue color develop-
ment after addition of the horseradish peroxidase substrate is inversely
proportional to the amount of 8-isoprostane in the samples and stan-
dards and changes to yellow after stopping the reaction with acid. Ab-
sorbance is measured at 450 nm.
Measurement of endothelial dysfunction
Urinary 8-OHdG was determined by a 8-hydroxy-2-deoxy Guano-
sine EIA Kit (Cayman Chemical, USA), which is a competitive assay,
using an anti-mouse IgG-coated plate and a tracer consisting of an 8-
OHdG-acetylcholinesterase conjugate instead of an antigen-coated
plate to improve sensitivity and reduce variability. 8-OHdG in the sam-
ple competes with the 8-OHdG-enzyme conjugate (tracer) for a con-
stant amount of 8-OHdG monoclonal antibody. The tracer-antibody-
complex binds to the pre-coated anti-mouse IgG and addition of
AChE-substrate (acetylcholine and 5,5′-dithio-bis-2-nitrobenzoic aid)
results in the enzymatic production of a yellow 5-thio-2-nitrobenzoic
acid, which can be measured spectrophotometrically at 412 nm and is
inversely proportional to the amount of 8-OHdG in the original sample.
Quantiﬁcation of creatinine in the urine samples was done by Dorevitch
Pathology Laboratory, Albury, NSW to normalize both 8-isoprostane
and 8-OHdG values.
Plasma homocysteine was determined by the automated AxSYM®
system(Abbott Laboratories, USA),whichuses a two-step reaction (1. re-
duction of protein-bound homocysteine by dithiothreitol, 2. enzymatic
conversion of free homocysteine to S-adenosylhomocysteine in the pres-
ence of adenosine). The product of reaction 2 (S-adenosylhomocysteine)
is detected by a ﬂuorescence polarization immunoassay.
Measurement of inﬂammation
Plasma IL-6 was determined by an Interleukin-6 (human) EIA Kit
(Cayman Chemical, USA), which uses a double-antibody sandwich
ELISA strategy. Free IL-6 in the samples binds to the pre-coated mono-
clonal antibody speciﬁc for IL-6 and an acetylcholinesterase:IL-6 Fab′
conjugate binds selectively to a different epitope on the IL-6 molecule.
Addition of AChE-substrate (acetylcholine and 5,5′-dithio-bis-2-
nitrobenzoic acid) results in the enzymatic production of the yellow 5-thio-2-nitrobenzoic acid, which absorbs at 412 nm. The color develop-
ment is directly proportional to the concentration of IL-6 in the sample.
Serum CRP levels were provided by Dorevitch Pathology Laboratory,
Albury, NSW.
Measurement coagulation and ﬁbrinolysis
Plasma C5a was determined by the Human C5a ELISA Kit II (BD Bio-
sciences, USA), which is a sandwich ELISA assay usingmonoclonal anti-
body speciﬁc for human C5a pre-coated on microplates. The second
antibody, which binds to immobilized C5a, is an anti-human C5a anti-
body — streptavidin horseradish peroxidase conjugate, which reacts
with a peroxidase substrate (TMB) to a blue product. The reaction is
stopped by addition of phosphoric acid, which changes the color to yel-
low. Absorbance can bemeasured at 450 nmand is directly proportional
to the amount of C5a in the initial sample.
D-Dimer levels were provided by Dorevitch Pathology Laboratory,
Albury, NSW.
Statistical analysis
Sample concentrations were calculated using Microsoft Excel
(Ofﬁce2007, Microsoft) and descriptive data is expressed as mean ±
standard deviation (x ± SD). Statistical analysis was performed with
SPSS (Version 20, IBM Co). To determine if there were signiﬁcant differ-
ences in biomarker levels between the control and prediabetes group a
Student t-test was used. A p-value b0.05 was considered as signiﬁcant.
Results
Table 1 shows the main characteristics and biomarker results of the
two groups. The control and prediabetic subjects were comparable
concerning age (61.81 ± 11.58 and 66.99 ± 10.82), distribution of gen-
der (slightly higher proportion of females: 59.9% and 54.6%) and BMI
(26.29 ± 4.64 and 28.22 ± 5.12, p N 0.05). The prediabetes group had
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and some minor differences were present in the medication status.
While the percentage of subjects on antihypertensives was remarkably
higher in the prediabetes group (35.8%) compared to the control group
(5.2%), the number of subjects on statins and anticoagulants (aspirin/
clopidogrel) was relatively small in both control (b4%) and prediabetes
group (b16%). The blood lipid levels showed only minimal differences
between both groups, being slightly improved in the prediabetes
group with signiﬁcant lower total cholesterol (p = 0.02) and HDL
(p = 0.004) in the latter.
Reduced glutathione levels were slightly increased in the prediabe-
tes group, while the increase in oxidized glutathione (GSSG) levels
compared to controlwas a bitmore prominent. Neither of them showed
signiﬁcant changes. However, the GSH/GSSG ratio was signiﬁcantly
(p = 0.001) decreased in the prediabetes group. No difference
was found in the 8-isoprostane levels between both groups (control:
0.21 ± 0.16, prediabetes: 0.23 ± 0.19 mg/mmol creatinine).
Both urinary 8-OHdG and plasma homocysteine levels were signiﬁ-
cantly higher (p = 0.04 and p = 0.01, respectively) in the prediabetes
group compared to control.
We also observed increased inﬂammation in the prediabetes group,
represented by elevated CRP (control: 3.05± 2.30, prediabetes: 3.69±
2.72 mmol/L) and IL-6 levels (control: 28.66 ± 28.43, prediabetes:
34.37 ± 33.72 pg/mL) in the prediabetes group compared to control,
both with a p-value b0.1.
The same trend was found for the coagulation/ﬁbrinolysis status.
Both C5a (control: 19.32 ± 20.04, prediabetes: 21.91 ± 21.03 ng/mL)
andD-Dimer (control: 0.46±0.30, prediabetes: 0.54±0.37 μg/L) levels
were increased in the prediabetic subjects, but the differences did not
reach signiﬁcance (p N 0.05).
Discussion
Prediabetes is the asymptomatic stage of diabetes mellitus and
might be a useful target for early intervention therapies to prevent the
development of this wide-spread disease and its associated complica-
tions like cardiovascular disease. We focused on changes in biomarkers,
which can already be seen in the prediabetic state, to provide new
knowledge about disease progression and possible tools for prevention
screening programs. Based on the deﬁnition of prediabetes in this study
as elevated fasting blood glucose levels between 5.6 and 6.9 mmol/L we
expected to ﬁnd adverse effects of mild hyperglycaemia manifested in
impaired biomarker levels in the prediabetes group.
Unexpectedly, the prediabetic subjects were characterized by a
slightly improved blood lipid proﬁle. A possible explanation for that
phenomenon is that even though the differences in statin use between
the two groupswere only small, this could still have had an inﬂuence on
the blood lipid outcomes of the prediabetes group, since statins lower
LDL and increase HDL levels.
A very important ﬁnding was the signiﬁcantly decreased GSH/GSSG
ratio in the prediabetes group,which indicates an impaired redox status
in the prediabetes group compared to the controls. This result proves
the presence of increased oxidative stress already at the prediabetes
state, which is represented by a slight increase in GSSG levels together
with a signiﬁcant decrease in GSH/GSSG ratio in the prediabetes
group. This is consistent with earlier ﬁndings, which showed that
changes in the antioxidant status, especially the glutathione system of
the erythrocytes, characterize the initial phase of oxidative stress in di-
abetes mellitus progression and commence prior to the establishment
of this disease [28]. Theminimal increase in GSH levels in the prediabe-
tes group could be due to the antioxidant effect of hypoglycaemic and
cardiovascular disease medication. Another possible explanation is an
activation of GSH synthesis in response to increased GSSG formation
due to increased oxidative stress, probably caused by higher amounts
of ROS in the erythrocytes. Dincer et al. proved that oxidative stress in-
hibits the activity of glutathione reductase, the enzyme that regeneratesGSH from GSSG [18], an effect, which could also contribute to the in-
creased GSSG levels and new synthesis of GSH. As a second marker for
oxidative stresswe chose 8-isoprostane, because it is said to be a reliable
indicator of oxidative stress and lipid peroxidation in humans [37].
Physiologically, 8-isoprostane is generated through the non-enzymatic
oxidation of phospholipids containing arachnidonic acid and then ex-
creted into the urine [31]. Our study did not ﬁnd any changes in urinary
8-isoprostane levels from control to prediabetic subjects, indicating that
the antioxidant system of the prediabetic subjects, including the GSH/
GSSG cycling, was still capable of preventing further oxidative damage
to lipids. Thereforewe conclude, that urinary 8-isoprostane is not sensi-
tive enough to be a useful biomarker in the screening for prediabetes.
The strongest evidence for altered functional status at the prediabetic
state compared to controlwere the signiﬁcant changes in endothelial dys-
function related to levels of 8-OHdG. 8-OHdG is a product of DNA base
modiﬁcation at the C-8 site produced by oxidation of deoxyguanosine
[29]. It is the most sensitive marker of oxidative DNA damage and more-
over, reﬂects total systemic oxidative stress in vivo [20,38]. In addition, 8-
OHdG is an established risk marker for atherosclerosis and diabetes
mellitus and it has been shown that urinary 8-OHdG is more stable than
serum 8-OHdG [39], which is why we chose to use urine samples for
the measurement of this marker. Homocysteine is a cytotoxic amino
acid, which is secreted into the plasma from endothelial and red blood
cells as a product of incomplete conversion of methionine to cysteine,
reﬂecting increased oxidative stress [40]. Studies on the connection be-
tween plasma homocysteine level and CVD risk have been controversial,
with some authors claiming an association [41] and some denying the ef-
ﬁcacy of lowering the homocysteine levels as a means of preventing the
CVD incidence [42]. There is however consensus about the prothrombotic
and prooxidant properties of homocysteine, which can cause the forma-
tion of ROS and contribute to endothelial dysfunction [40–42]. Homocys-
teine can moreover inhibit the expression of antioxidant enzymes like
glutathione peroxidase-1, which has the consequence that the regenera-
tion of reduced glutathione is limited [41]. In this studywe foundnot only
signiﬁcantly higher 8-OHdG (p=0.04), but surprisingly also signiﬁcantly
increased homocysteine levels (p = 0.009) in the prediabetic subjects
compared to control. The elevated 8-OHdG level together with the im-
paired GSH/GSSG ratio is consistent with earlier ﬁndings, where serum
8-OHdG and glutathione status have been measured [29,38]. Urinary 8-
OHdG can bemeasured non-invasively and the samples are easier to han-
dle compared to blood, which makes it a better alternative to the tradi-
tional serum 8-OHdG, if it shows the same sensitivity. We have shown
that the measurement of urinary 8-OHdG gives the same results for pre-
diabetic patients as themeasurement of serum8-OHdG. The elevated ho-
mocysteine was unexpected, but shows once more that increased
oxidative stress is accompaniedwith changes in intracellularmetabolism,
as in the case of cysteine production, and endothelial dysfunction,
reﬂected in the elevated plasma homocysteine levels. However, it is also
possible that homocysteine contributes itself to the oxidative stress by
stimulation the formation of ROS. Either way, the association is apparent
and homocysteine seems to be elevated already in the prediabetic state.
These results prove that the relatively small elevation of blood glucose
levels in the prediabetic state has a detectable inﬂuence on endothelial
function, resulting in increased DNA-damage and homocysteine release
from endothelial cells. Increased oxidative stress as measured by the im-
paired GSH/GSSG ratio is likely to be the link between the moderate
hyperglycaemia in prediabetes and pathological changes in endothelial
function, which in the long-term may promote atherogenesis and result
in the development of cardiovascular disease.
The observed non-signiﬁcant but consistent trend of increased in-
ﬂammation and coagulation in prediabetesmeasured by slightly elevat-
ed CRP, IL-6, C5a and D-Dimer reﬂects the pathological consequences of
hyperglycaemia-induced oxidative stress in prediabetes and underlines
the ﬁndings that have been discussed above. CRP is the golden marker
of inﬂammation and is said to be a better predictor of CVD risk than
LDL [43] and elevated levels of both CRP and IL-6 predict the
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since the prediabetic subjects showed higher levels of both markers
compared to control, which shows the importance of assessingmarkers
of inﬂammation in screening for prediabetes, early detection of the pre-
clinical state is essential. C5a is a potent proinﬂammatory complement
component, which among others induces adhesion molecule expres-
sion and tissue factor activity in endothelial cells. It is therefore involved
in coagulation pathways [44] D-Dimer is an indicator of coagulation ac-
tivity, since it is the product of the enzymatic degradation of ﬁbrin, a
process called ﬁbrinolysis [45]. Both increased and decreased levels
have so far been reported in diabetes mellitus patients [46]. Our results
showed that there is a trend towards elevated C5a andD-Dimer levels in
the prediabetic subjects, which indicates that there probably is a slightly
increased coagulation activity already in the prediabetic state, leading
the way for future cardiovascular complications.
To our knowledge, this studywas the ﬁrst one that examined chang-
es in oxidative stress, endothelial dysfunction, inﬂammation and coagu-
lation/ﬁbrinolysis together in a prediabetes group compared to controls.
The results show that the onset of endothelial dysfunction and in-
creased oxidative stress manifest early in disease progression and are
detectable as changes in biomarker levels are already at the prediabetic
state. Also the tendency towards increased inﬂammation and coagula-
tion was noticeable in the prediabetic subjects, being well-known risk
factors for the development of macrovascular complications. These
ﬁndings not only prove once more, that prediabetes is a clinical state
that needs to be taken seriously since it is the precursor of diabetes,
but muchmore importantly offer reliable tools for early detection of di-
abetes development and the associated complications like cardiovascu-
lar disease in prevention screenings.
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